Written Question · S3W-40250 · Session 3
What assessment it has made of equity of access to orphan and ultra-orphan medicines between (a) NHS boards and (b) Scotland and other UK n…
The question
To ask the Scottish Executive what assessment it has made of equity of access to orphan and ultra-orphan medicines between (a) NHS boards and (b) Scotland and other UK nations.
The answer
Decisions regarding the introduction of new medicines are taken by each of the UK countries through their own appraisal arrangements in line with established national priorities.
Scotland''s independent, robust and transparent arrangements for the appraisal of all newly licensed medicines focus on patients having equitable access to clinically and cost-effective medicines to treat all conditions throughout all parts of Scotland.
Decisions regarding the provision of NHS services are matters for NHS boards and clinicians are responsible for clinical decisions regarding the care of individual patients.
Equity of access to healthcare more generally is considered by the World Health Organization and other international organisations.
Scotland''s independent, robust and transparent arrangements for the appraisal of all newly licensed medicines focus on patients having equitable access to clinically and cost-effective medicines to treat all conditions throughout all parts of Scotland.
Decisions regarding the provision of NHS services are matters for NHS boards and clinicians are responsible for clinical decisions regarding the care of individual patients.
Equity of access to healthcare more generally is considered by the World Health Organization and other international organisations.
In the Official Report
No contribution in the Official Report cites S3W-40250 by reference.